Area of research
Cardiology and Cardiovascular Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Acute Myocardial Infarction Research, Atrial Fibrillation Management and Outcomes, Antiplatelet Therapy and Cardiovascular Diseases, and Heart Failure Treatment and Management.
Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial.
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial.
Non-ST-segment elevation acute coronary syndrome: understanding the full spectrum to guide management.
Decentralized clinical trials in cardiovascular disease : A primer for clinical trialists.
Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administration.
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin.
The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study.
Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.
Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.
Network Meta-Analysis With Individual Participant-Level Data of Time-to-Event Outcomes Using Cox Regression.
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials.
Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.
Differences in Care and Outcomes in Cardiogenic Shock in Cardiac Intensive Care Units in the United States and Canada: CCCTN Registry Insights.
Impact of timing of treatment for cardiac implantable electronic device infections on healthcare utilization and expenditures.
Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.
Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: A subgroup analysis of ARTESiA
Clinical implications of perioperative and periprocedural myocardial infarction.
Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry
Public awareness of automated external defibrillator (AED)s and their location: Results of a cross-sectional survey in North Carolina.
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
Embedding Implementation Science in Clinical Trials: A Framework for Academic-Life Science Partnerships.
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension.
Abstract 4346591: Cardiovascular Diagnoses Following Smartwatch Irregular Pulse Notifications: Insights from the Apple Heart Study
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation
Apixaban vs Aspirin According to CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.